Eris Lifesciences · NSE: ERIS · BSE: 540596

Q3 FY26 results · Oct–Dec 2025

Eris Lifesciences reported revenue from operations of ₹807.45 crore (up 11.0% from Q3 FY25) and net profit of ₹108.83 crore (up 25.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	807.45	727.45	+11.0%	792.41	+1.9%
Other income	0.02	4.22	−99.5%	2.81	−99.3%
Total income	807.47	731.67	+10.4%	795.22	+1.5%
Profit before share of associates & JVs and tax	145.23	116.16	+25.0%	172.39	−15.8%
Share of profit/(loss) of associates & JVs	0.12	0.00		0.28
Net profit for the period	108.83	86.93	+25.2%	134.47	−19.1%
Attributable to shareholders of the company	99.72	83.62	+19.2%	120.19	−17.0%
EPS, basic (₹)	7.32	6.15	+18.9%	8.82	−17.0%
Net margin (%)	13.5	11.9		17.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	315.29	399.73	−21.1%	650.50	−51.5%
Other income	25.07	7.79	+221.8%	23.59	+6.3%
Total income	340.36	407.52	−16.5%	674.09	−49.5%
Profit before tax	3.89	6.03	−35.5%	234.67	−98.3%
Net profit for the period	3.09	1.78	+73.6%	149.57	−97.9%
EPS, basic (₹)	0.23	0.13	+75.6%	10.98	−97.9%
Net margin (%)	1.0	0.4		23.0

Consolidated

Filed with BSE: 13 Feb 2026, 16:16 IST
Board meeting: 13 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Feb 2026, 16:16 IST
Board meeting: 13 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE